The reduction or loss of E-cadherin (E-cad), a calcium-dependent epithelial cell adhesion molecule, has been associated with tumor dedifferentiation and invasiveness. The immunohistochemical pattern of E-cad expression was evaluated in formalin-fixed and paraffin-embedded sections of 6 normal mammary glands, 3 dysplasias, 12 benign tumors (8 benign mixed tumors, 4 adenomas), and 60 malignant tumors (12 stage 0, 29 stage I, 19 stage II) of the canine mammary gland. E-cadherin expression was classified as membranous, when on cell-cell boundaries, or as cytoplasmic, when in the form of a diffuse cytoplasmic staining. In addition, the percentage of E-cad-positive epithelial neoplastic cells was graded by a semiquantitative method, categorizing cases into a reduced (or Ϫ) type group, when showing less than 25% positivity, a reduced (or ϩ/Ϫ) type group, when showing 25-75% positivity, and a preserved (or ϩ) type group, when more than 75% positive cells were present. In the normal mammary gland, E-cad expression was evident in epithelial luminal cells. A stronger positivity was revealed in ductular than in alveolar luminal cells. The myoepithelial cells showed inconsistent, weak cytoplasmic positivity in the normal gland as well as in mammary tumors. In normal glands and benign and malignant noninvasive tumors, E-cad expression was mainly membranous and preserved in most of the epithelial cells. In stage I tumors, both membranous (38%) and cytoplasmic (62%) positivity were well represented, as well as preserved type (55%) and reduced type (45%) tumors. All stage II malignant tumors showed the highest frequency of cytoplasmic positivity (79%) and reduced type (62%) tumors.
Introduction
Cadherins are a family of structurally highly homologous transmembrane glycoproteins involved in calcium-dependent homotypic cell-cell adhesion. These proteins are important during embryonic development and for the maintenance of adult tissue architecture; moreover, mounting evidence suggests that cadherin adhesion plays a signaling role during cell growth and differentiation. 11 Several types of these adhesion molecules have been identified, including E-, P-, and N-cadherins: E-cadherin (E-cad), the major transmembrane component of adherens junctions in most epithelial cells, is primarily localized at the lateral cell borders. It is composed of an extracellular domain that dimerizes selectively to an identical structure on an adjacent cell, a transmembrane domain, and an intracytoplasmic domain. The intracytoplasmic domain is linked to actin filaments by means of associated cytoplasmic proteins called catenins, which allow the connection of the cell surface to the cytoskeleton. 21 The importance of E-cad in cancer biology is supported by large numbers of studies implicating cadherins in tumorigenesis and neoplastic invasion. Most studies focus on the capability of E-cad to act as a suppressor of invasion, thereby preventing tumor cells from migrating away from their primary location. 7 Invasion of cancer cells depends on defects in normal intercellular cohesion, for which reduced or lost E-cad expression can be responsible. The loss of adhesion function has been associated with malignancy, anaplastic phenotypes, and increased metastatic potential in human carcinomas. 6 Downregulation or reduction of E-cad function caused by mutations in the Ecad gene (CDH1 in humans) has been reported in invasive carcinomas of the breast, bladder, endometrium, liver, lung, ovary, prostate, and thyroid. 3 The availability of different antibodies recognizing cadherins in paraffin sections has allowed the correlation of reduced or lost E-cad immunohistochemical expression with the lack of cohesiveness, higher malignant potential, and invasiveness of epithelial neoplasms of the colon, ovary, stomach, pancreas, lung, breast, head and neck, and other sites in humans. 4 Despite the large number of studies performed in human medicine, few studies have investigated E-cad expression in normal and neoplastic animal tissues to better understand the role played by this molecule during cancerogenesis. 19 The purpose of this study is to analyze the immunohistochemical expression of E-cad in canine mammary tumors using a canine cross-reacting mouse anti-human E-cad antibody and to correlate its expression pattern with tumor morphology and histopathological staging.
Materials and methods
In a retrospective study, 81 mammary gland biopsies were collected that were derived from 81 mastectomies performed at the Clinic of Veterinary Surgery (School of Veterinary Medicine, University of Bologna, Italy) and in private clinics between 1992 and 1997. Sixty of the 81 dogs were affected by malignant primary mammary tumors, 12 by benign mammary tumors, and 3 by dysplasia. The remaining 6 were control mammary gland samples.
All samples were immediately fixed in 10% buffered formalin and routinely processed for histopathology. Histologic diagnoses were obtained on hematoxylin and eosin-stained slides according to a published method 16 ; in malignant tumors, the histologic stage of invasion was determined according to a previously proposed system 9 : stage 0 ϭ tumors without stromal invasion; stage I ϭ tumors with stromal invasion; and stage II ϭ tumors with neoplastic emboli in vessels or lymph node metastases (or both). For each tumor, a 4-m-thick section was used for E-cad immunohistochemistry.
E-cadherin immunohistochemistry
The sections were dewaxed in toluene and rehydrated. Endogenous peroxidase was blocked by immersion in 0.3% hydrogen peroxide for 30 min. Sections were then rinsed in Tris buffer, immersed in citrate buffer (2.1 g citric acid monohydrate/liter distilled water), pH 6.0, incubated for 10 min in a microwave oven at 750 W, and allowed to cool down at room temperature (approximately 20 min). The primary anti-E-cad antibody, clone 36 a (mouse anti-human, 2.5 g/ml), was used for its property of cross-reacting with canine tissues as indicated in the manufacturer's datasheet. This antibody was applied overnight at 4Њ C and was followed by a commercial streptavidin-biotin-peroxidase. b In negative control sections, the primary antibody was replaced with phosphate-buffered saline. Sections of normal mammary glands were used as positive controls.
Evaluation of E-cad immunoreactivity
E-cadherin pattern. E-cadherin immunoreactivity was classified according to its prevalent pattern of expression as membranous, when the immunolabeling was localized on cell-cell boundaries, or as cytoplasmic, when the positivity was uniformly distributed throughout the cytoplasm.
E-cadherin grade. On the basis of the proportion of epithelial E-cad-positive cells, E-cad expression of tumors was semiquantitatively evaluated and classified into 3 grades, grouping cases showing Ͼ75% (E-cad positive (ϩ) group), from 25% to 75% (E-cad heterogeneous (ϩ/Ϫ) group), and Ͻ25% of cancer-positive cells (E-cad negative (Ϫ) group). The E-cad (ϩ) tumors were classified as preserved E-cad expression type (Pr type), whereas the (ϩ/Ϫ) and (Ϫ) tumor groups were classified as reduced E-cad expression type (Rd type).
Statistical analysis
Correlation between E-cad expression and histologic stage, benign versus malignant tumors, and histologic type has been investigated by the Pearson method and tested for significance using the chi-square test using a software package. c P Ͻ 0.05 was considered significant.
Results
All 81 biopsies were examined microscopically by 2 pathologists (GS and CB) according to a published method, 16 and the following diagnoses were made: 3 ductal ectasias and hyperplasias, 12 benign tumors (4 simple adenomas, 8 benign mixed tumors), and 60 malignant neoplasms. These were 33 tubulopapillary carcinomas (8 stage 0, 18 stage I, and 7 stage II), 12 carcinomas in benign tumors (4 stage 0, 6 stage I, and 2 stage II), 13 solid carcinomas (4 stage I and 9 stage II), 1 stage I squamous cell carcinoma, and 1 stage II carcinosarcoma.
Immunohistochemical expression of E-cad
Immunohistochemical expression of E-cad in normal mammary glands was characterized by continuous brown staining on cell-cell boundaries of epithelial luminal cells of ducts ( Fig. 1a ) and glands. A stronger positivity was revealed in ductular compared with alveolar luminal cells. Myoepithelial cells had an inconstant and weaker cytoplasmic immunolabeling, whereas nonepithelial cells such as fibroblasts or inflammatory cells (lymphocytes, plasma cells) were E-cad negative. In dysplasias, both ductal ectasias and hyperplasias revealed a strong membranous staining of duct luminal cells. In contrast to normal and dysplastic epithelial cells, different E-cad staining patterns and grades of expression were revealed in benign and malignant mammary tumors. Thirty-five (49%) of the 72 benign ( Fig. 1b ) and malignant tumors revealed membranous staining, whereas 37 (51%) revealed a cytoplasmic positivity ( Table 1 ; Fig. 1c ). Of the 72 tumors, 42 (58%) tumors were classified as Pr type and 30 tumors (42%) as Rd type ( Table 2) . A significant correlation exists between group type (normal gland, dysplasia, and benign and malignant tumors) and E-cad pattern (P ϭ 0.0057) ( Fig. 2) but not E-cad grade (P ϭ 0.076).
Benign lesions
Detailed results are summarized in Tables 1, 2 . E-cadherin pattern. Nine of 12 (75%) benign mammary neoplastic lesions exhibited a membranous pattern similar to the luminal epithelium of normal mammary glands; 3 cases (25%) had a uniformly distributed positivity in the cell cytoplasm. Chondrocytes showed cytoplasmic positivity in only 1 case of benign mixed tumor (Fig. 1d ). E-cadherin grade. Eight (67%) and 4 (33%) of the 12 benign tumors were classified as Pr type and Rd type, respectively.
Malignant lesions
Detailed results are summarized in Tables 1, 2 . E-cadherin pattern. All the 60 malignancies stained positive for E-cad but with 2 different patterns. Twenty-six of 60 (43%) malignant tumors stained positive along the lateral cell borders of intercellular contact (membranous pattern), whereas 34 cases (57%) had a cytoplasmic pattern. Ductules revealed a stronger positivity than lobular cells in malignant tumors, as is in normal mammary gland and benign tumors.
E-cadherin grade. Thirty-four (57%) malignant tu-mors were classified as Pr type and 26 (43%) as Rd type.
Correlation of E-cad expression with histologic classification
The membranous staining pattern of E-cad prevailed in dysplasias and in the 2 benign histological types singularly evaluated (100% for dysplasias, 75% for both benign mixed tumors and simple adenomas). Similar percentages were obtained computing the frequency of Pr types (100% for ductal ectasias, 75% for benign mixed tumors, and 50% for simple adenomas). The 2 benign histotypes presented no significant difference in the percentage of membranous/cytoplasmic (P ϭ 0.88) or Pr/Rd (P ϭ 0.38) types. Table 1 . Correlation of E-cad pattern of expression with histologic type and stage of canine mammary tumors. Among malignant tumors, the percentage of membranous pattern was significantly lower in solid carcinomas compared with tubulopapillary carcinomas and carcinomas in benign tumor (P ϭ 0.0041) and significantly higher in stage 0 compared with stages I and II (P ϭ 0.00041). In malignant tumors, E-cad pattern significantly correlated with histologic type (P ϭ 0.0041). Squamous cell carcinoma and carcinosarcoma were excluded from the statistical analysis because each histotype was represented in single cases. Tubulopapillary carcinoma was the only type in which the frequency of membranous pattern cases (57.58%) was higher than that of cytoplasmic pattern tumors. In malignant mixed tumors, the percentage of membranous pattern was lower (41.67%) than that of the cytoplasmic pattern, whereas all solid carcinomas had cytoplasmic positivity. The trend for E-cad grade was less evident than that for E-cad pattern (P ϭ 0.042). Squamous cell carcinoma and carcinosarcoma were again excluded from the analysis because they encompass only 1 case for histotype. The frequency of Rd type (76.92%) was much higher than that of Pr type in solid carcinomas. As for the other histologic types, the percentage of Pr type compared with Rd type was 63.64% for tubulopapillary carcinomas and 58.33% for carcinomas in benign tumors.
Correlation of E-cad expression with histologic stage
The relationship between E-cad expression and histological stage is shown in Tables 1, 2. The frequency of membranous pattern was clearly higher in stage 0 tumors (92%) than in stage I and II neoplasms (38% and 21%, respectively) (P ϭ 0.00041), proving its highest frequency in noninfiltrating tumors. In infiltrating tumors, instead, the prevalent pattern was the Rd type. In fact, it accounted for 45% of stage I and 62% of stage II tumors (P ϭ 0.010), whereas it was observed in only 1 of 12 grade 0 tumors (8%).
Discussion
The intercellular adhesion molecule E-cad is the major cadherin expressed by epithelial cells in human breast tissue, where it helps maintain normal structural architecture. 10 Levels of E-cad and ␣and ␤-catenins, cytoplasmic components of adherens junctions, are high at the basolateral boundary in luminal epithelia and low in myoepithelial cells. 10, 12 In contrast, only low levels of ␣2 and ␣3 subunits of the ␤1 integrin family have been detected at the basolateral surface of luminal epithelial cells, whereas large amounts of these molecules were found in the myoepithelium. 10 Using immunohistochemistry, E-cad expresses a membranous pattern in the epithelial cells in normal canine mammary glands and in the majority of benign mammary tumors examined. 19 Myoepithelial cells are inconstantly and less positive for E-cad compared with mammary epithelial cells in canine mammary tissues. 15, 19 In this study, about 50% of carcinomas had a reduced E-cad grade of expression (Rd type), and half of them had heterogeneous (ϩ/Ϫ) expression. These data suggest that the progression of the normal epithelial phenotype to that typical of malignancies may be associated with the progressive loss of intercellular adhesion mediated by E-cad.
In several types of carcinomas recently studied, 8,17 decreased E-cad expression is associated with a lack of histologic differentiation, allowing the disruption of cell-cell adhesion and the infiltration of the neoplastic cells in the surrounding tissue and, finally, promoting the formation of metastases. 6, 19 In this study, the prevalence of tumors with reduced E-cad expression in sol- Table 2 . Correlation of E-cad grade of expression with histologic type and stage of canine mammary tumors. Among malignant tumors, solid carcinomas have a statistically lower percentage of Pr type compared with tubulopapillary carcinomas and carcinomas in benign tumors (P ϭ 0.042), whereas a statistically lower percentage of Rd type pattern was found in stage 0 compared with stages I and II (P ϭ 0.010). id type tumors compared with tubular and tubulopapillary types correlates well with the absence of histological differentiation. Loss of E-cad expression in breast cancer cells can occur by means of multiple mechanisms, including complete or partial gene deletion, promoter inactivation by methylation, and chromatin rearrangement. 13 However, the mechanisms whereby tumor cells exhibit decreased E-cad expression appear quite complex and, to date, are poorly understood. Several studies have demonstrated that nor-mal immunohistochemical expression of E-cad can be associated with a compromised functional ability (i.e., immunohistochemistry marks the protein and its localization but it does not give indications about its function) and alterations in the expression of the catenins can be seen despite retained E-cad expression. 14 In general, the membranous pattern is prevalent in normal mammary gland and benign tumors, whereas the cytoplasmic pattern is more frequent in malignant types and, above all, in solid carcinomas. On the basis of the above results, the pattern of expression of Ecad results in a stronger parameter than the grade of expression in discriminating between benign and malignant tumors or histotypes. Malignant and invasive tumors are characterized by an increased E-cad cytoplasmic distribution. However, the question concerning the significance of this type of positivity is still debated. Some authors explain the cytoplasmic immunohistochemical staining pattern as the result of a failure in the translocation or in the anchorage of E-cad to the cell membrane 18, 20 ; some others consider it a functional defect of its cytoplasmic tail, which cannot bind the intracellular catenins. 5 Most of the malignant tumors from the file comprising the cases used in this study may reflect an alteration of E-cad localization, probably because of a loss of the transmembrane and cytoplasmic domains of the protein, which affects the correct membranous localization. 2 Besides indicating an abnormal E-cad expression in canine mammary carcinomas, this study also points out a close relationship between E-cad expression and histologic stage or invasiveness established by a widely accepted gradation method. 9 Noninvasive tumors do not show any alterations in E-cad expression, whereas a progressive increase in the number of cases with reduced E-cad expression and cytoplasmic pattern is evident from tumors with stromal invasion (stage I) to neoplasms with neoplastic emboli in vessels (stage II). It is well known that E-cad is well expressed in differentiated and noninvasive human carcinoma cell lines of various origin, including the breast, whereas less-differentiated and invasive carcinoma cell lines lose expression, supporting a role of E-cad for the suppression of invasiveness. 7, 17 Difficulties exist in comparing the number of studies reported in human literature because of differences in tissue preparation, antibodies used, and immunohistochemical methods. However, most of these studies provide that, generally, in human breast tumors reduced E-cad expression is significantly more frequently found in invasive than in noninvasive carcinomas, suggesting that loss of E-cad expression is associated with the development of an invasive carcinoma phenotype. 8, 21 An exception to this rule is inflammatory breast carcinoma in which E-cad overexpression parallels sialyl-Lewis X/A underexpression. 1 The prognostic role played by E-cad in the dog seems promising but needs to be confirmed by more survival data collected during a period of at least 2 years.
